company background image
4568 logo

Daiichi Sankyo Company TSE:4568 Stock Report

Last Price

JP¥5.66k

Market Cap

JP¥10.8t

7D

-4.2%

1Y

37.5%

Updated

26 Jul, 2024

Data

Company Financials +

Daiichi Sankyo Company, Limited

TSE:4568 Stock Report

Market Cap: JP¥10.8t

4568 Stock Overview

Manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally.

4568 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance5/6
Financial Health6/6
Dividends3/6

Daiichi Sankyo Company, Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Daiichi Sankyo Company
Historical stock prices
Current Share PriceJP¥5,658.00
52 Week HighJP¥6,109.00
52 Week LowJP¥3,566.00
Beta0.24
11 Month Change0.11%
3 Month Change12.93%
1 Year Change37.50%
33 Year Change162.01%
5 Year Change152.29%
Change since IPO633.22%

Recent News & Updates

Daiichi Sankyo Company (TSE:4568) Is Due To Pay A Dividend Of ¥30.00

Jul 26
Daiichi Sankyo Company (TSE:4568) Is Due To Pay A Dividend Of ¥30.00

Daiichi Sankyo Company's (TSE:4568) Dividend Will Be ¥30.00

Jul 12
Daiichi Sankyo Company's (TSE:4568) Dividend Will Be ¥30.00

Recent updates

Daiichi Sankyo Company (TSE:4568) Is Due To Pay A Dividend Of ¥30.00

Jul 26
Daiichi Sankyo Company (TSE:4568) Is Due To Pay A Dividend Of ¥30.00

Daiichi Sankyo Company's (TSE:4568) Dividend Will Be ¥30.00

Jul 12
Daiichi Sankyo Company's (TSE:4568) Dividend Will Be ¥30.00

Here's Why Daiichi Sankyo Company (TSE:4568) Has Caught The Eye Of Investors

May 22
Here's Why Daiichi Sankyo Company (TSE:4568) Has Caught The Eye Of Investors

Statutory Profit Doesn't Reflect How Good Daiichi Sankyo Company's (TSE:4568) Earnings Are

May 02
Statutory Profit Doesn't Reflect How Good Daiichi Sankyo Company's (TSE:4568) Earnings Are

Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Apr 27
Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Daiichi Sankyo Company (TSE:4568) Is Paying Out A Larger Dividend Than Last Year

Mar 11
Daiichi Sankyo Company (TSE:4568) Is Paying Out A Larger Dividend Than Last Year

Daiichi Sankyo Company (TSE:4568) Will Pay A Larger Dividend Than Last Year At ¥30.00

Feb 26
Daiichi Sankyo Company (TSE:4568) Will Pay A Larger Dividend Than Last Year At ¥30.00

Shareholder Returns

4568JP PharmaceuticalsJP Market
7D-4.2%0.5%-5.2%
1Y37.5%17.2%15.6%

Return vs Industry: 4568 exceeded the JP Pharmaceuticals industry which returned 15.8% over the past year.

Return vs Market: 4568 exceeded the JP Market which returned 15.7% over the past year.

Price Volatility

Is 4568's price volatile compared to industry and market?
4568 volatility
4568 Average Weekly Movement4.4%
Pharmaceuticals Industry Average Movement4.0%
Market Average Movement3.7%
10% most volatile stocks in JP Market7.3%
10% least volatile stocks in JP Market1.8%

Stable Share Price: 4568 has not had significant price volatility in the past 3 months.

Volatility Over Time: 4568's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
189918,726Sunao Manabewww.daiichisankyo.com

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with acute myeloid leukemia; and Injectafer, a ferric carboxymaltose injection to treat iron deficiency. It also provides Liziana and Savaysa, direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT antihypertensive agents; Nilemdo, an oral treatment which lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe to reduce cholesterol; and Efient, an anti-platelet agent.

Daiichi Sankyo Company, Limited Fundamentals Summary

How do Daiichi Sankyo Company's earnings and revenue compare to its market cap?
4568 fundamental statistics
Market capJP¥10.80t
Earnings (TTM)JP¥200.73b
Revenue (TTM)JP¥1.60t

53.8x

P/E Ratio

6.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4568 income statement (TTM)
RevenueJP¥1.60t
Cost of RevenueJP¥415.32b
Gross ProfitJP¥1.19t
Other ExpensesJP¥985.64b
EarningsJP¥200.73b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Jul 31, 2024

Earnings per share (EPS)105.14
Gross Margin74.07%
Net Profit Margin12.53%
Debt/Equity Ratio6.0%

How did 4568 perform over the long term?

See historical performance and comparison

Dividends

1.1%

Current Dividend Yield

48%

Payout Ratio

Does 4568 pay a reliable dividends?

See 4568 dividend history and benchmarks
When do you need to buy 4568 by to receive an upcoming dividend?
Daiichi Sankyo Company dividend dates
Ex Dividend DateSep 27 2024
Dividend Pay DateDec 09 2024
Days until Ex dividend61 days
Days until Dividend pay date134 days

Does 4568 pay a reliable dividends?

See 4568 dividend history and benchmarks
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.